I now agree... .high 60's and beyond will happen as MA deal gets closer to happening.
The current market cap represents only a portion of the cash TZYM has in the bank right now. Add in the Match and and other IP related assets, this would be a very easy aquisition for Bristol-Myers to justify for instance at $30M+ (double current market cap).
Given that their last collaboration with Tranzyme using its MATCH technology cost them about 80 million, it could be argued that even 30M is cheap. If MATCH is really that effective in helping discover new drugs, it could be worth billions in the long run. I'm not suggestion a buyout in the billions, but it could easily be 100M or more. Short-term, I really can't say, but long-term, if Stifel is worth their salt, they could bid this thing up until it's a 5-10 bagger.
Agreed, rather than pay $80M each time for their services, Bristol-Myers or someone else will just buy them. Amazing we are currently at only a $15M mkt cap. I suspect this statement in the press release "has not made a decision to pursue any specific transaction" indicates there are multiple opportunities/bids they are evaluating.